Preparation method and application of Mn2 + / mannosylated dual-modified phage with double-layer helmet structure
Through the Mn2+/mannose double-modified phage with a double-layer helmet structure, the mannose and Mn2+ of the phage are used to activate macrophages, the problem of poor antibiotic treatment effect in hospital-acquired infection is solved, and the multidrug-resistant bacteria are achieved The efficient clearance and local immune reconstruction provide an innovative endogenous antibacterial strategy.
Patent Information
- Application Number
- CN202410956789.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-22
AI Technical Summary
The incidence of hospital-acquired infections is increasing year by year, and the existing antibiotic treatment is not effective, especially for multidrug-resistant bacteria, and the local immunosuppressive environment is difficult to effectively remove bacteria.
The Mn2+/mannose double-modified phage with a double-layer helmet structure was prepared by phage screening technology, surface chemical grafting method and electrostatic adsorption method. The mannose and Mn2+ of the phage are used to activate macrophages to provide recognition sites and immunity. Activation layer enables targeted markers and immune reconstruction of pathogens.
It significantly improves the phagocytosis ability and local immune activity of macrophages, reverses the immunosuppressive microenvironment, effectively eliminates pathogens, reduces the severity of infection and bacterial load, and provides an endogenous antibacterial strategy.
Smart Images

Figure CN118995637A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of antibacterial, and in particular to a double-layer helmet structure Mn 2+ / Mannosylated double-modified phage preparation method and application. Background Art
[0002] Hospital-acquired infection (Nosocomial Infection) has always been a difficult problem faced in clinical practice. With the abuse of antibiotics and the increase in drug-resistant strains in recent years, the incidence rate has increased year by year. According to statistics, the incidence rate of hospital-acquired infection has reached 3-25%, and 20-30% of deaths are directly related to hospital-acquired infection, depending on the national economic situation and medical level. Hospital-acquired infection is expensive to treat, with poor treatment effects and poor prognosis, which has brought great pressure to patients and medical insurance expenditures. The main method for preventing nosocomial infection in clinical practice is still to strengthen nursing care and the use of preventive antibiotics, but there are many limitations (such as high nursing costs and liver and kidney toxicity of antibiotics) and the effect is not good. For nosocomial infections that have already occurred, they can only be treated by continuously upgrading antibiotics, and they are often helpless against multidrug-resistant bacteria. For this reason, it is urgent to develop an efficient treatment method for nosocomial infection.
[0003] Due to the strong drug resistance of multi-drug resistant bacteria, conventional antibiotic treatment is almost ineffective against them. The infected area is often in an immunosuppressive environment, and local immune cells are difficult to play a bactericidal role. Therefore, activating the body's own immunity to kill bacteria may be a feasible method. To this end, the present invention constructs a double-layer helmet structure Mn 2+ / Mannosylated double-modified phages, using specific phages to target and label pathogens, and the mannose groups on their surface can provide recognition sites for macrophages, Mn 2+ It can activate macrophages and restore their phagocytic ability, thereby effectively reversing the local immunosuppressive microenvironment and achieving the purpose of treating hospital-acquired infections. Summary of the invention
[0004] The present invention utilizes bacteriophage, NHS-PEG-MAN, Mn 2+ Salt and other raw materials were used to prepare a double-layer helmet structure Mn by combining phage screening technology, surface chemical grafting method, electrostatic adsorption method and other combined processes. 2+ / mannose double modified phage and use, the specific scheme of the present invention is as follows:
[0005] A double-layer helmet structure 2+ The preparation method of the double-modified phage with mannosylation is as follows:
[0006] 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology;
[0007] 2) dissolving the E. coli phage obtained in step 1) in deionized water to prepare a phage solution; adding an appropriate amount of N-hydroxysuccinimide-polyethylene glycol-mannose (NHS-PEG-MAN) to the phage solution to form an organic targeting layer structure after surface chemical grafting reaction; and obtaining a mannosylated water-soluble modified phage after dialysis and freeze-drying;
[0008] 3) The water-soluble modified phage modified by mannosylation obtained in step 2) is dissolved again in deionized water to obtain a mannosylated modified phage solution, and an appropriate amount of Mn is added to the solution. 2+ salt and stir to absorb Mn by electrostatic adsorption 2+ Mineralization on the prepared mannosylated water-soluble phage forms a double inorganic immune activation layer structure; Mn 2+ / mannosylation double-modified phage.
[0009] Further, in step 1), the concentration of the Escherichia coli liquid is 10 8 -10 9 CFU / ml, the concentration of LB medium was 75g / ml.
[0010] Furthermore, in step 1), the specific type of the Escherichia coli phage is a myotail phage, whose major axis length is 150-170nm and zeta potential is -13--17mV.
[0011] Further, in step 2), the concentration of the phage solution is 5-20*10 6 PFU / ml; NHS-PEG-MAN concentration is 0.1-0.5mg / ml, where PEG length is 1000-4000.
[0012] Further, in step 2), during the surface chemical grafting reaction, the pH value of the phage solution is 7.5-8.0, the magnetic stirring rate is 400-600 rpm, the reaction time is 8-16 h, and the temperature is room temperature;
[0013] During the dialysis process, the dialysate is deionized water with a pH of 7.5-8.0, the dialysis temperature is room temperature, the dialysate is changed every 24 hours, and the dialysis process lasts for 2-3 days.
[0014] Further, in step 3), the Mn 2+ Salt is MnCl 2, concentration is 10-50ug / ml, add MnCl 2 The pH of the solution was adjusted to 7.5-8.0.
[0015] Further, in step 3), the concentration of the mannosylated modified phage solution is 5-20*10 6 PFU / ml;
[0016] The stirring process is specifically as follows: the magnetic stirring rate is 400-600 rpm, the reaction time is 8-16 h, and the temperature is room temperature;
[0017] The dialysate during the dialysis process is deionized water, the dialysis temperature is room temperature, and the liquid is changed every 24 hours for 2-3 days.
[0018] A double-layer helmet structure 2+ / Application of mannosylated double-modified bacteriophage, double-layer helmet structure Mn prepared by any of the preparation methods described in 2+ / Mannosylated double-modified phage is used to prepare reagents that can target and mark pathogens and mediate immune reconstruction.
[0019] Compared with the prior art, the present invention has the following advantages:
[0020] 1. The present invention utilizes bacteriophage, NHS-PEG-MAN, MnCl 2 etc. as raw materials, a double-layer helmet structure Mn was prepared through a combination of phage screening technology, surface chemical grafting method, electrostatic adsorption method, and metal ion biomineralization. 2+ / Mannosylated double-modified phage, which is original to the present invention;
[0021] 2. The present invention independently designs and prepares a Mn with a double-layer helmet structure. 2+ / mannosylation double modified phage biological target, which was prepared by surface chemical grafting and electrostatic adsorption. The E. coli phage has a typical head-tail structure to ensure its anchoring function to pathogens. As a biological entity, the carboxyl group on the phage surface is grafted with the amino group on NHS-PEG-MAN to form an organic targeting layer structure on the phage surface, providing abundant macrophage recognition and phagocytosis sites; and Mn 2+Through electrostatic adsorption and chelation with the carboxyl groups on the surface of the phage, a double inorganic immune activation layer structure is formed on the surface of the phage, and the modified phage is released after targeting the infection site, ensuring that the immune cells can remain activated. And the process parameters are also designed specifically according to the actual experimental scenario: considering that excessive amide bond connection may bind to the phage tail fiber, and the phage tail fiber plays a vital role in the targeting of pathogens, choosing a concentration of NHS-PEG-MAN below 0.5mg / ml can ensure that the surface chemical grafting mainly occurs on the head of the phage, maintaining the integrity of the tail fiber used by the phage to invade pathogens; at the same time, considering that excessive manganese ion concentration will cause heart function damage, so choosing MnCl below 50ug / ml 2 The concentration is to ensure the biocompatibility of the biological target. Therefore, in the present invention, only NHS-PEG-MAN and mineralized Mn are grafted on the head surface of the bacteriophage entity. 2+ Thin layer, forming a double-layer helmet structure with an organic targeting structure and a double-layer inorganic immune activation layer structure. 2+ / mannosylation double-modified phage.
[0022] 3. Without affecting Mn 2+ / The mannosylated double-modified phage biological target improves bacterial anchoring and biocompatibility while enhancing the performance of biological target-mediated immune reconstruction, which is original to the present invention;
[0023] 4. The double-modified phage designed and prepared in the present invention has pathogen targeting and killing functions, macrophage binding function, immune cell activation function, and biocompatibility. The above multiple properties meet the requirements for immune reconstruction at the infection site through synergistic enhancement: the local area around the infection site is in an immunosuppressive state, and bacteria have the ability to easily undergo phenotypic conversion to escape the nonspecific recognition of immune cells, which can easily lead to persistent infection. Therefore, the present invention innovatively uses phage, an ancient phage predator, to specifically target and mark bacteria, and at the same time grafts NHS-PEG-MAN on the surface of the phage to provide mannose residues for binding to macrophages to mediate phagocytosis of bacteria, greatly increasing the probability of macrophages recognizing and phagocytosing bacteria; in addition, considering that the local infection microenvironment may significantly inhibit the activity and antibacterial ability of immune cells, and Mn 2+ It has been proven in many studies that it can improve the phagocytic activity of macrophages. Therefore, we use the negative charge on the surface of the phage head to make the phage adsorb Mn by regulating the pH. 2+ , Mn 2+Mineralized in the phage head and released at the site of infection, macrophages can efficiently phagocytize pathogens on the basis of efficient identification of pathogens, and form a synergistic effect with the bacteriophage's own bactericidal function, achieving the purpose of reversing the local immune microenvironment and rebuilding the body's immune defense line to overcome refractory infections. This strategy is highly innovative and feasible, and is original to the present invention;
[0024] 5. The present invention innovatively uses bacteriophages to mark pathogens and adsorbs immune cell activation factors on the surface of bacteriophages, so that the bacteriophages play a "bridge" role. This strategy is extremely feasible and expansible: once the infection of pathogens is confirmed, the type of bacteriophages that can specifically identify the pathogens can be screened out. By modifying the bacteriophages and adsorbing immune activation factors, it can simultaneously promote recognition and function. This two-pronged approach greatly enhances local immune activity. It is an endogenous antibacterial strategy with good application prospects, and this strategy is original to the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 Mn 2+ / Process for preparing mannosylated double-modified phage;
[0026] Figure 2 Mn 2+ / Schematic diagram of reversal of local immunosuppressive microenvironment by mannosylated double-modified phage;
[0027] Figure 3 Mn 2+ / SEM image of mannosylated double-modified phage (Example 1);
[0028] Figure 4 Mn 2+ / Quantification of the in vitro antibacterial effect of mannosylated double-modified phages (co-cultured with macrophages and coated, left is comparative example 1, right is example 1);
[0029] Figure 5 Mn 2+ Quantification of the in vivo antibacterial effect of the double-modified phage with mannosylation (local Grams staining counts, left is Comparative Example 1, right is Example 1). DETAILED DESCRIPTION
[0030] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0031] Comparative Example 1:
[0032] 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology;
[0033] 2) Dissolve the bacteriophage obtained in step 1) in deionized water to prepare 1*10 7 The phage solution of PFU / ml is freeze-dried to obtain the phage.
[0034] The concentration of the Escherichia coli solution in this comparative example was 5×10 8 CFU / ml, the concentration of LB medium is 75g / ml, the specific type of E. coli phage isolated is myotail phage, its major axis length is about 160nm, and the ζ potential is about -15mV; the phage is added to the co-culture system of E. coli and macrophages, and then the system is plated, and the colony count is 530±89. Figure 4 Left bar graph: A subcutaneous E. coli infection model was established in rats. After the above phage was injected, samples were taken 14 days later, showing that the local infection reaction was severe, with pus flowing out. The Grams staining of the local section showed that the number of bacteria was 892±153. Figure 5 Left bar graph.
[0035] Example 1
[0036] 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology;
[0037] 2) Dissolve the bacteriophage obtained in step 1) in deionized water to prepare 1*10 7 PFU / ml phage solution; adding 0.3 mg / ml NHS-PEG-MAN to the above phage solution, adjusting the pH to between 7.5-8.0 with NaOH, reacting with magnetic stirring at 500 rpm / min for 12 hours, and then dialyzing the sample with deionized water at room temperature for 48 hours, changing the solution every 24 hours, and maintaining the pH at 7.5-8.0 with NaOH; freeze-drying after dialysis to obtain a mannosylated water-soluble modified phage.
[0038] 3) The mannosylated water-soluble modified phage obtained in step 2) is dissolved again in deionized water to obtain a mannosylated water-soluble modified phage solution, wherein the concentration of the mannosylated water-soluble modified phage is 1*10 7 PFU / ml, add 30ug / ml MnCl 2, adjust the pH to 7.5-8.0 with NaOH, and react with magnetic stirring at 500 rpm for 12 h at room temperature to obtain Mn 2+ / mannosylation double modified phage, such as Figure 3 This is the SEM image of Example 1.
[0039] Compared with Comparative Example 1, this embodiment increases the grafting of NHS-PEG-MAN with Mn 2+ The adsorption of the E. coli in this example is 5×10 8 CFU / ml, the concentration of LB medium is 75g / ml, the specific type of E. coli phage isolated is myotail phage, its major axis length is about 160nm, and the ζ potential is about -15mV; the phage is added to the co-culture system of E. coli and macrophages, and then the system is plated, and the colony count is 36±8. Figure 4 Right bar graph: A subcutaneous E. coli infection model was established in rats. After the above phage was injected, samples were taken 14 days later and showed that the local infection reaction was mild. The bacterial count of the local section by Grams staining was 97±21. Figure 5 Right bar graph.
[0040] Example 2
[0041] 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology;
[0042] 2) Dissolve the bacteriophage obtained in step 1) in deionized water to prepare 1*10 7 PFU / ml phage solution; adding 0.3 mg / ml NHS-PEG-MAN to the above phage solution, adjusting the pH to between 7.5 and 8.0 with NaOH, reacting with magnetic stirring at 500 rpm for 12 hours, and then dialyzing the sample with deionized water at room temperature for 48 hours, changing the solution every 24 hours, and maintaining the pH at 7.5-8.0 with NaOH; freeze-drying after dialysis to obtain a mannosylated water-soluble modified phage.
[0043] Compared with Example 1, this example eliminates the Mn 2+ The adsorption of the immune cells decreased, the bacterial load increased, but the bacterial load was lower than that of Comparative Example 1. The concentration of the E. coli solution in this example was 5×10 8CFU / ml, the concentration of LB culture medium was 75g / ml, and the specific type of Escherichia coli phage isolated was myotail phage, with a long axis length of about 160nm and a ζ potential of about -15mV; the phage was added to the co-culture system of Escherichia coli and macrophages, and then the system was plated, and the colony count was 348±62; a subcutaneous Escherichia coli infection model of the back of rats was established, and after injection of the above-mentioned phage, sampling 14 days later showed that the local infection reaction was more severe, and the bacterial count of local sections by Grams staining was 695±103.
[0044] Example 3
[0045] 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology;
[0046] 2) Dissolve the bacteriophage obtained in step 1) in deionized water to prepare 1*10 7 PFU / ml phage solution; adding 0.01 mg / ml NHS-PEG-MAN to the above phage solution, adjusting the pH to between 7.5 and 8.0 with NaOH, reacting with magnetic stirring at 500 rpm for 12 hours, and then dialyzing the sample with deionized water at room temperature for 48 hours, changing the solution every 24 hours, and maintaining the pH at 7.5-8.0 with NaOH; freeze-drying after dialysis to obtain a mannosylated water-soluble modified phage.
[0047] 3) The mannosylated water-soluble modified phage obtained in step 2) is dissolved again in deionized water to obtain a mannosylated water-soluble modified phage solution, wherein the concentration of the mannosylated water-soluble modified phage is 1*10 7 PFU / ml, add 30ug / ml MnCl 2 , adjust the pH to 7.5-8.0 with NaOH, and react with magnetic stirring at 500 rpm for 12 h at room temperature to obtain Mn 2+ / mannosylation double-modified phage.
[0048] Compared with Example 1, this example reduces the grafting of NHS-PEG-MAN, and macrophages cannot effectively identify and remove the labeled pathogens. The bacterial load increases, but it is lower than that of Comparative Example 1. The concentration of the E. coli solution in this example is 5×10 8CFU / ml, the concentration of LB culture medium was 75g / ml, and the specific type of Escherichia coli phage isolated was myotail phage, with a long axis length of about 160nm and a ζ potential of about -15mV; the phage was added to the co-culture system of Escherichia coli and macrophages, and then the system was plated, and the colony count was 256±39; a subcutaneous Escherichia coli infection model of the back of rats was established, and after injection of the above-mentioned phage, sampling 14 days later showed that the local infection reaction was more severe, and the bacterial count of the local section Grams staining was 581±97.
[0049] like Figure 2 The local infection microenvironment may significantly inhibit the activity and antibacterial ability of immune cells, while Mn 2+ The phagocytic activity of macrophages can be improved. Therefore, the present invention utilizes the negative charge characteristics of the phage head surface and controls the pH to make the phage adsorb Mn 2+ , Mn 2+ Mineralized in the phage head and released at the infection site, macrophages can efficiently phagocytize pathogens while efficiently identifying them, forming a synergistic effect with the bacteriophage's own bacteriocidal function, achieving the purpose of reversing the local immune microenvironment and rebuilding the body's immune defense line to overcome refractory infections.
[0050] This double-layer helmet structure Mn2+ / mannose-modified phage can achieve the re-recognition and activation of pathogens by immune cells through the "bridge" effect, reverse the local immunosuppressive microenvironment of infection, and thus achieve bacterial clearance, showing great potential in various in vivo antibacterial applications.
[0051] This double-layer helmet structure Mn2+ / mannosylation double-modified phage is also used to prepare reagents that can target and mark pathogens and mediate immune reconstruction.
Claims
1. A double-layer helmet structure Mn 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: The specific steps are as follows: 1) Collect medical sewage samples, mix the sample supernatant with Escherichia coli culture medium in LB medium for phage amplification, filter and sterilize the mixture, and screen and isolate Escherichia coli phages through double-layer agar plate phage screening technology; 2) dissolving the E. coli phage obtained in step 1) in deionized water to prepare a phage solution; adding an appropriate amount of N-hydroxysuccinimide-polyethylene glycol-mannose (NHS-PEG-MAN) to the phage solution to form an organic targeting layer structure after surface chemical grafting reaction; and obtaining a mannosylated water-soluble modified phage after dialysis and freeze-drying; 3) The water-soluble modified phage modified by mannosylation obtained in step 2) is dissolved again in deionized water to obtain a mannosylated modified phage solution, and an appropriate amount of Mn is added to the solution. 2+ salt and stir to absorb Mn by electrostatic adsorption 2+ Mineralization on the prepared mannosylated water-soluble phage forms a double inorganic immune activation layer structure; Mn 2+ / mannosylation double-modified phage.
2. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 1), the concentration of Escherichia coli solution is 10 8 -10 9 CFU / ml, the concentration of LB medium was 75g / ml.
3. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 1), the specific type of the Escherichia coli phage is a myotail phage, which has a major axis length of 150-170 nm and a zeta potential of -13--17 mV.
4. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 2), the concentration of the phage solution is 5-20*10 6 PFU / ml; NHS-PEG-MAN concentration is 0.1-0.5mg / ml, where PEG length is 1000-4000.
5. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 2), during the surface chemical grafting reaction, the pH value of the phage solution is 7.5-8.0, the magnetic stirring rate is 400-600 rpm, the reaction time is 8-16 h, and the temperature is room temperature; During the dialysis process, the dialysate is deionized water with a pH of 7.5-8.0, the dialysis temperature is room temperature, the dialysate is changed every 24 hours, and the dialysis process lasts for 2-3 days.
6. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 3), the Mn 2+ The salt is MnCl2, the concentration is 10-50ug / ml, and the pH of the solution after adding MnCl2 is adjusted to 7.5-8.
0.
7. A double-layer helmet structure Mn according to claim 1 2+ / A method for preparing a mannosylated double-modified bacteriophage, characterized in that: In step 3), the concentration of the mannosylated modified phage solution is 5-20*10 6 PFU / ml; During the stirring process, the magnetic stirring rate is 400-600 rpm, the reaction time is 8-16 h, and the temperature is room temperature; The dialysate during the dialysis process is deionized water, the dialysis temperature is room temperature, and the liquid is changed every 24 hours for 2-3 days.
8. A double-layer helmet structure Mn 2+ / Application of a mannosylated double-modified bacteriophage, characterized in that, A double-layer helmet structure Mn prepared by the preparation method according to any one of claims 1 to 7 2+ / Mannosylated double-modified phage is used to prepare reagents that can target and mark pathogens and mediate immune reconstruction.
